Literature DB >> 10945620

Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling.

E Badia1, M J Duchesne, A Semlali, M Fuentes, C Giamarchi, H Richard-Foy, J C Nicolas, M Pons.   

Abstract

Antiestrogen resistance is frequently observed in patients after longterm treatment with tamoxifen, a nonsteroidal antiestrogen widely used for endocrine therapy of breast cancer. In vitro studies in resistant cells showed that the expression of natural estrogen-responsive genes is frequently altered. Using MVLN cells, an MCF-7-derived cell model, we previously demonstrated that 4-hydroxytamoxifen (OHT) treatment irreversibly inactivated an estrogen-regulated chimeric luciferase response by a direct effect of the drug and not through a cell selection process (E. Badia et al., Cancer Res., 54: 5860-5866, 1994). In the present study, we present tamoxifen-resistant but still estrogen-dependent clones isolated after long-term treatment of MVLN cells with OHT and show that progesterone receptor (PR) expression was irreversibly decreased in some of these clones, whereas the PRA:PRB ratio of residual PR remained unchanged. The irreversible inactivation of both chimeric luciferase gene and PR gene expression was associated with the disappearance of DNase 1-hypersensitive sites. In the case of the chimeric gene, at least one of these sites was close to the estrogen responsive element. Genomic sequencing analysis of a clone with very low PR content did not reveal any methylation on CpG dinucleotides or any mutation in the PR gene promoter region. In all of the resistant clones tested and independently of their PR content, estrogen receptor expression was only lowered by half and remained functional, whereas pS2 expression was not modified. We also observed that the residual luciferase activity level (1-2%) of the MVLN clones, the luciferase expression of which had been irreversibly inactivated, was raised 4-fold by trichostatin A treatment. We conclude that long-term OHT treatment may modify the chromatin structure and thus could contribute to differentially silencing natural target genes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945620

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Genetic and epigenetic regulation of AHR gene expression in MCF-7 breast cancer cells: role of the proximal promoter GC-rich region.

Authors:  Neal A Englert; Robert J Turesky; Weiguo Han; Erin E Bessette; Simon D Spivack; Michele Caggana; David C Spink; Barbara C Spink
Journal:  Biochem Pharmacol       Date:  2012-06-21       Impact factor: 5.858

Review 2.  Epigenetic alteration by the chemical substances, food and environmental factors.

Authors:  Hideki Fukata; Chisato Mori
Journal:  Reprod Med Biol       Date:  2004-08-10

3.  Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development.

Authors:  Stephen F Madden; Mattia Cremona; Angela M Farrelly; Weng Hei Low; Jean McBryan
Journal:  Cancer Gene Ther       Date:  2022-10-20       Impact factor: 5.854

4.  Epigenetic Therapy in Breast Cancer.

Authors:  Maryam B Lustberg; Bhuvaneswari Ramaswamy
Journal:  Curr Breast Cancer Rep       Date:  2011-03

Review 5.  Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.

Authors:  Eric Badia; Joan Oliva; Patrick Balaguer; Vincent Cavaillès
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

6.  A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.

Authors:  Nhan T Nguyen; Julie A Vendrell; Coralie Poulard; Balázs Győrffy; Sophie Goddard-Léon; Ivan Bièche; Laura Corbo; Muriel Le Romancer; Thomas Bachelot; Isabelle Treilleux; Pascale A Cohen
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

7.  High-density array analysis of DNA methylation in Tamoxifen-resistant breast cancer cell lines.

Authors:  Kristin E Williams; Douglas L Anderton; Maxwell P Lee; Brian T Pentecost; Kathleen F Arcaro
Journal:  Epigenetics       Date:  2013-11-13       Impact factor: 4.528

Review 8.  Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response.

Authors:  Thushangi N Pathiraja; Vered Stearns; Steffi Oesterreich
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-01-27       Impact factor: 2.673

9.  Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.

Authors:  Andrew Stone; Fatima Valdés-Mora; Julia M W Gee; Lynne Farrow; Richard A McClelland; Heidi Fiegl; Carol Dutkowski; Rachael A McCloy; Robert L Sutherland; Elizabeth A Musgrove; Robert I Nicholson
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

Review 10.  Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.

Authors:  Rocío García-Becerra; Nancy Santos; Lorenza Díaz; Javier Camacho
Journal:  Int J Mol Sci       Date:  2012-12-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.